Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

Takeshi Harada, MD, Shuji Ozaki, MD, PhD, Asuka Oda, PhD, Masami Iwasa, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Hirokazu Miki, MD, PhD, Kumiko Kagawa, MD, PhD, Masahiro Abe, MD, PhD, Hironobu Shibata, MD, PhD, Akishige Ikegame, MD, PhD, Daisuke Tsuji, PhD, Kohji Itoh, PhD, Masaki Ri, MD, PhD, Shinsuke Iida, MD, PhD, Yukimasa Shiotsu, PhD, Shigeto Kawai, PhD, Hisafumi Yamada-Okabe, PhD, Toshio Matsumoto, MD, PhD

Blood (2012) 120 (21): 1839.

https://doi.org/10.1182/blood.V120.21.1839.1839

Published: 2012

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

Journal Articles

Identification of Toyocamycin, an Agent Cytotoxic for Multiple Myeloma Cells, As a Potent Inhibitor of ER Stress-Induced XBP1 mRNA Splicing

Blood (2012) 120 (21): 5034.

https://doi.org/10.1182/blood.V120.21.5034.5034

Published: 2012

Journal Articles

Reduced Expression of HDAC3 Contributes to the Resistance Against HDAC Inhibitor, Vorinostat (SAHA) in Mature Lymphoid Malignancies

Jianming (Diane) Ding, MD, PhD, Masaki Ri, MD, PhD, Tomoko Narita, MD, Ayako Masaki, MD, Fumiko Mori, MD, Asahi Ito, MD, PhD, Shigeru Kusumoto, MD, PhD, Takashi Ishida, MD, PhD, Hirokazu Komatsu, MD, PhD, Yukimasa Shiotsu, PhD, Akio Niimi, MD, PhD, Shinsuke Iida, MD, PhD

Blood (2012) 120 (21): 1342.

https://doi.org/10.1182/blood.V120.21.1342.1342

Published: 2012

Journal Articles

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Hirokazu Miki, MD, Masahiro Abe, MD, PhD, Kumiko Kagawa, MD, Asuka Oda, PhD, Hiroe Amou, PhD, Akishige Ikegame, PhD, Keiichiro Watanabe, DDS, Masahiro Hiasa, DDS, Takeshi Harada, MD, Shiro Fujii, MD, Shingen Nakamura, MD, Ayako Nakano, MD, PhD, Kyoko Takeuchi, MD, PhD, Shuji Ozaki, MD, PhD, Yukimasa Shiotsu, PhD, Masaki Ri, MD, Shinsuke Iida, MD, PhD, Toshio Matsumoto, MD, PhD

Blood (2011) 118 (21): 5104.

https://doi.org/10.1182/blood.V118.21.5104.5104

Published: 2011

Journal Articles

Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis.

Kensuke Kojima, MD, PhD, Marina Konopleva, MD, PhD, Twee Tsao, Michael Andreeff, MD, PhD, Hiroshi Ishida, Yukimasa Shiotsu, PhD, Linhua Jin, PhD, Yoko Tabe, MD, PhD, Hideki Nakakuma, MD, PhD

Blood (2009) 114 (22): 2597.

https://doi.org/10.1182/blood.V114.22.2597.2597

Published: 2009

Journal Articles

Establishment and Characterization of Bortezomib-Resistant Myeloma Cell Lines: A Possible Role of Mutated Proteasome β5 Subunit in Preventing the Accumulation of Unfolded Protein, Which Is Otherwise Followed by Catastrophic Endoplasmic Reticulum (ER) Stress.

Masaki Ri, Shinsuke Iida, Takayuki Nakashima, Hideyuki Miyazaki, Fumiko Mori, Asahi Ito, Atsushi Inagaki, Shigeru Kusumoto, Takashi Ishida, Hirokazu Komatsu, Yukimasa Shiotsu, Ryuzo Ueda

Blood (2009) 114 (22): 3772.

https://doi.org/10.1182/blood.V114.22.3772.3772

Published: 2009

Journal Articles

Anti–leukemia Activity of a Novel KIT Selective Inhibitor KI–328.

Akane Tsujimura, MD, Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, Ph.D., Yuichi Ishikawa, MD, PhD, Hiroshi Ishida, Tsutomu Toki, PhD, Etsuro Ito, MD, PhD, Tomoki Naoe, MD, PhD

Blood (2009) 114 (22): 4146.

https://doi.org/10.1182/blood.V114.22.4146.4146

Published: 2009

Journal Articles

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

Yukimasa Shiotsu, Hitoshi Kiyoi, Yuichi Ishikawa, Ryohei Tanizaki, Makiko Shimizu, Hiroshi Umehara, Kenichi Ishii, Yumiko Mori, Kazutaka Ozeki, Yosuke Minami, Akihiro Abe, Hiroshi Maeda, Tadakazu Akiyama, Yutaka Kanda, Yuko Sato, Shiro Akinaga, Tomoki Naoe

Blood (2009) 114 (8): 1607–1617.

https://doi.org/10.1182/blood-2009-01-199307

Published: 2009

Journal Articles

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

Keith W. Pratz, Jorge Cortes, Gail J. Roboz, Niranjan Rao, Omotayo Arowojolu, Adam Stine, Yukimasa Shiotsu, Aiko Shudo, Shiro Akinaga, Donald Small, Judith E. Karp, Mark Levis

Blood (2009) 113 (17): 3938–3946.

https://doi.org/10.1182/blood-2008-09-177030

Published: 2009

Journal Articles

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

Toshihiko Ishii, Asher Alban Chanan-Khan, MD, Jazur Jafferjee, MD, Noreen Ersing, Takeshi Takahashi, PhD, Masato Mizutani, PhD, Yukimasa Shiotsu, PhD, Nobuo Hanai, PhD

Blood (2008) 112 (11): 1718.

https://doi.org/10.1182/blood.V112.11.1718.1718

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Ryohei Tanizaki, MD, PhD, Yosuke Minami, MD, PhD, Akihiro Abe, MD, PhD, Yuichi Ishikawa, MD, PhD, Kenichi Ishii, Makiko Shimizu, Yutaka Kanda, PhD, Yuko Sato, MD, PhD, Shiro Akinaga, PhD, Jorge Cortes, MD, Tomoki Naoe, MD, PhD

Blood (2008) 112 (11): 1640.

https://doi.org/10.1182/blood.V112.11.1640.1640

Published: 2008

Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel

Blood (2008) 112 (11): 1625.

https://doi.org/10.1182/blood.V112.11.1625.1625

Published: 2008

Journal Articles

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Yukimasa Shiotsu, PhD, Hitoshi Kiyoi, MD, PhD, Kazutaka Ozeki, MD, PhD, Hiroshi Umehara, Makiko Shimizu, Shiro Akinaga, PhD, Tomoki Naoe, MD, PhD

Blood (2007) 110 (11): 1832.

https://doi.org/10.1182/blood.V110.11.1832.1832

Published: 2007

Journal Articles

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G 1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

Yukimasa Shiotsu, Leonard M. Neckers, Ivo Wortman, Won G. An, Theodor W. Schulte, Shiro Soga, Chikara Murakata, Tatsuya Tamaoki, Shiro Akinaga

Blood (2000) 96 (6): 2284–2291.

https://doi.org/10.1182/blood.V96.6.2284

Published: 2000

Journal Articles

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia

Yukimasa Shiotsu, Kinya Yamashita, Fumihiko Kanai, Yoji Ikuina, Chikara Murakata, Masanao Teramura, Hideaki Mizoguchi, Tatsuya Tamaoki, Shiro Akinaga

Blood (2000) 95 (12): 3771–3780.

https://doi.org/10.1182/blood.V95.12.3771

Published: 2000

NARROW

Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Identification of Toyocamycin, an Agent Cytotoxic for Multiple Myeloma Cells, As a Potent Inhibitor of ER Stress-Induced XBP1 mRNA Splicing

Reduced Expression of HDAC3 Contributes to the Resistance Against HDAC Inhibitor, Vorinostat (SAHA) in Mature Lymphoid Malignancies

Potentiation of bortezomib's Anti-Myeloma Effects in Combination with Anti-DR5 Agonistic Antibody: The Role of ER Stress in DR5 Editing and DR-Mediated Apoptotic Signaling

Selective FLT3 Inhibitor FI-700 Neutralizes Mcl-1 and Enhances p53-Mediated Apoptosis in Acute Myeloid Leukemia (AML) Cells with Activating Mutations of FLT3 Via Mcl-1/Noxa Axis.

Establishment and Characterization of Bortezomib-Resistant Myeloma Cell Lines: A Possible Role of Mutated Proteasome β5 Subunit in Preventing the Accumulation of Unfolded Protein, Which Is Otherwise Followed by Catastrophic Endoplasmic Reticulum (ER) Stress.

Anti–leukemia Activity of a Novel KIT Selective Inhibitor KI–328.

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

A Humanized Anti-Ganglioside GM2 Antibody, BIW-8962, Exhibits ADCC/CDC Activity against Multiple Myeloma Cells and Potent Anti- Tumor Activity in Mouse Xenograft Models.

KW-2449, a Novel Multi-Kinase Inhibitor, Suppresses the Growth of Imatinib-Resistant Ph+ Leukemia Including BCR-ABL/T315I Both in Vitro and in Vivo.

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

KW-2449, a Novel Multi-Kinase Inhibitor Against FLT3, Abl, FGFR1 and Aurora, Suppresses the Growth of AML Both In Vitro and In Vivo .

Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G 1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex

Chemoprotective effects of KF41399, a derivative of carbazole compounds, on nimustine-induced thrombocytopenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only